ADIL insider transaction filings

ADIAL PHARMACEUTICALS, INC. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen ADIL transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Coastlands Capital LP — 10% owner35 legs · 39,986 sh · $106,329
Young Wendy B. — Director11

Recent Form 4 filings — ADIAL PHARMACEUTICALS, INC.

FiledFormInsiderReported transactionsSource
2026-09-214Young Wendy B. — DirectorGrant/award (A): 25,666 (derivative) @ $0EDGAR
2026-07-164Coastlands Capital LP — 10% ownerPurchase (P): 2,000 @ $2.65 · Purchase (P): 1,233 @ $2.75EDGAR
2026-07-134Coastlands Capital LP — 10% ownerPurchase (P): 10,053 @ $2.79 · Purchase (P): 1,700 @ $2.70EDGAR
2026-07-014Coastlands Capital LP — 10% ownerPurchase (P): 25,000 @ $2.60EDGAR
2026-06-164Davidson Matt — Chief Development Officer, DirectorGrant/award (A): 61,647 · Grant/award (A): 3,427 · Grant/award (A): 232,417 @ $0 · Grant/award (A): 1,822.13 · Grant/award (A): 101.30 · Grant/award (A): 232,417 (derivative) @ $0EDGAR
2026-06-164Young Wendy B. — DirectorPurchase (P): 36,378 (derivative) @ $2.75EDGAR
2026-04-094Anderson J. Kermit — DirectorGrant/award (A): 9,185 (derivative) @ $0EDGAR
2026-04-094Goodman Tony — Chief Operating Officer, DirectorGrant/award (A): 26,510 @ $0EDGAR
2026-04-094Shah Vinay — Chief Financial OfficerGrant/award (A): 17,325 @ $0EDGAR
2026-04-094Schuyler Kevin — DirectorGrant/award (A): 9,185 @ $0EDGAR
2026-04-094Gilliland Robertson H. — DirectorGrant/award (A): 9,185 @ $0EDGAR
2026-04-094Claiborne Cary J — Chief Executive Officer, DirectorGrant/award (A): 37,985 @ $0EDGAR
2025-06-024Gilliland Robertson H. — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2025-06-024Newman James W. Jr. — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2025-06-024Shah Vinay — Chief Financial OfficerGrant/award (A): 9,000 (derivative) @ $0EDGAR
2025-06-024Schuyler Kevin — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2025-06-024Goodman Tony — Chief Operating Officer, DirectorGrant/award (A): 94,000 (derivative) @ $0EDGAR
2025-06-024Anderson J. Kermit — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2025-06-024Claiborne Cary J — Chief Executive Officer, DirectorGrant/award (A): 138,000 (derivative) @ $0EDGAR
2024-12-054Claiborne Cary J — Chief Executive Officer, DirectorGrant/award (A): 350,000 (derivative) @ $0EDGAR
2024-11-184Shah Vinay — Chief Financial OfficerGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-03-274Gilliland Robertson H. — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-03-274Newman James W. Jr. — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-03-274Truluck Joseph — Chief Financial OfficerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2024-03-274Anderson J. Kermit — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-03-274Schuyler Kevin — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-03-274Goodman Tony — Chief Operating Officer, DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2024-03-274Claiborne Cary J — Chief Executive Officer, DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR

Recent 8-K events — ADIAL PHARMACEUTICALS, INC.

FiledFormItems reportedSource
2026-09-188-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-168-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-258-K3.02 — Unregistered Sales of Equity SecuritiesEDGAR
2026-08-218-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-08-178-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-138-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
EDGAR
2026-08-118-K/A9.01 — Financial Statements and ExhibitsEDGAR
2026-06-118-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ADIL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →